Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo

Diabetes

Volumn 64, Issue 11, 2015, Pages 3914-3926

  Bharath, Leena P ^a,b   Ruan, Ting ^a,b   Li, Youyou ^a,b   Ravindran, Anindita ^a,b   Wan, Xin ^a,b   Nhan, Jennifer Kim ^a,b   Walker, Matthew Lewis ^a,b   Deeter, Lance ^a,b   Goodrich, Rebekah ^a,b   Johnson, Elizabeth ^a,b   Munday, Derek ^a,b   Mueller, Robert ^a,b   Kunz, David ^a,b   Jones, Deborah ^b   Reese, Van ^c   Summers, Scott A ^d   Babu, Pon Velayutham Anandh ^a   Holland, William L ^e   Zhang, Quan Jiang ^f   Abel, E Dale ^f   Symons, J David ^a,b   more..

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 90; INHIBITOR 2 OF PHOSPHOPROTEIN PHOSPHATASE 2A; PALMITIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; UNCLASSIFIED DRUG; MONOUNSATURATED FATTY ACID; PHOSPHOPROTEIN PHOSPHATASE 2; THERMOZYMOCIDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DIET INDUCED OBESITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENOTYPE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; AORTA; BOVINE; DRUG EFFECTS; METABOLISM; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; CATTLE; CELL MEMBRANE; CERAMIDES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; HSP90 HEAT-SHOCK PROTEINS; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; PALMITIC ACID; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84946441531     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0244     Document Type: Article

References (40)

1. Triggle CR, Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J Am Soc Hypertens 2010;4:102-115
2. Symons JD, Abel ED. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev Endocr Metab Disord 2013;14:59-68
3. Symons JD, McMillin SL, Riehle C, et al. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res 2009;104:1085-1094
4. Zhang QJ, Holland WL, Wilson L, et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 2012;61:1848-1859
5. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003;52:2882-2887
6. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230-1239
7. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610
8. Summers SA. Sphingolipids and insulin resistance: the five Ws. Curr Opin Lipidol 2010;21:128-135
9. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29:381-402
10. Wu Y, Song P, Xu J, Zhang M, Zou MH. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007;282:9777-9788
11. Mehra VC, Jackson E, Zhang XM, et al. Ceramide-activated phosphatase mediates fatty acid-induced endothelial VEGF resistance and impaired angiogenesis. Am J Pathol 2014;184:1562-1576
12. Lu J, Kovach JS, Johnson F, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 2009;106:11697-11702
13. Lu J, Zhuang Z, Song DK, et al. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg 2010;113:225-233
14. Martiniova L, Lu J, Chiang J, et al. Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. PLoS One 2011;6:e14678
15. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5:167-179
16. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995;211:396-403
17. Galbo T, Perry RJ, Nishimura E, Samuel VT, Quistorff B, Shulman GI. PP2A inhibition results in hepatic insulin resistance despite Akt2 activation. Aging (Albany, NY) 2013;5:770-781
18. Harris MB, Ju H, Venema VJ, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001;276:16587-16591
19. Yang D, Li Q, So I, et al. IRBIT governs epithelial secretion in mice by antagonizing the WNK/SPAK kinase pathway. J Clin Invest 2011;121:956-965
20. Chung H, Brautigan DL. Protein phosphatase 2A suppresses MAP kinase signalling and ectopic protein expression. Cell Signal 1999;11:575-580
21. Mukhopadhyay A, Saddoughi SA, Song P, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2009;23:751-763
22. Zhang QJ, McMillin SL, Tanner JM, Palionyte M, Abel ED, Symons JD. Endothelial nitric oxide synthase phosphorylation in treadmill-running mice: role of vascular signalling kinases. J Physiol 2009;587:3911-3920
23. Symons JD, Hu P, Yang Y, et al. Knockout of insulin receptors in cardiomyocytes attenuates coronary arterial dysfunction induced by pressure overload. Am J Physiol Heart Circ Physiol 2011;300:H374-H381
24. Rockstroh M, Muller S, Jende C, Kerzhner A, Bergen M, Tomm J. Cell fractionation - an important tool for compartment proteomics. J Integr OMICS 2011;01:135-143
25. Stein DT, Stevenson BE, Chester MW, et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 1997;100:398-403
26. Babu PV, Si H, Fu Z, Zhen W, Liu D. Genistein prevents hyperglycemiainduced monocyte adhesion to human aortic endothelial cells through preservation of the cAMP signaling pathway and ameliorates vascular inflammation in obese diabetic mice. J Nutr 2012;142:724-730
27. Wadsworth JM, Clarke DJ, McMahon SA, et al. The chemical basis of serine palmitoyltransferase inhibition by myriocin. J Am Chem Soc 2013;135:14276-14285
28. Saddoughi SA, Gencer S, Peterson YK, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013;5:105-121
29. Foulkes JG, Jefferson LS. Protein phosphatase-1 and -2A activities in heart, liver, and skeletal muscle extracts from control and diabetic rats. Diabetes 1984;33:576-579
30. Wei Q, Xia Y. Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 2006;281:21652-21659
31. Raichur S, Wang ST, Chan PW, et al. CerS2 haploinsufficiency inhibits b-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014;20:687-695
32. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014;20:678-686
33. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell 2009;139:468-484
34. Kowluru A, Matti A. Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes: potential mechanisms and functional consequences. Biochem Pharmacol 2012;84:591-597
35. Smith AR, Visioli F, Frei B, Hagen TM. Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramideactivated phosphatase 2A. Aging Cell 2006;5:391-400
36. Li M, Damuni Z. I1PP2A and I2PP2A. Two potent protein phosphatase 2Aspecific inhibitor proteins. Methods Mol Biol 1998;93:59-66
37. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996;271:11059-11062
38. Götz J, Schild A. Transgenic and knockout models of PP2A. Methods Enzymol 2003;366:390-403
39. Bonness K, Aragon IV, Rutland B, Ofori-Acquah S, Dean NM, Honkanen RE. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha. Mol Cancer Ther 2006;5:2727-2736
40. Du Y, Kowluru A, Kern TS. PP2A contributes to endothelial death in high glucose: inhibition by benfotiamine. Am J Physiol Regul Integr Comp Physiol 2010;299:R1610-R1617